Should You Buy Allarity Therapeutics, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Allarity Therapeutics, Inc. (ALLR) presents a moderate quality profile with a QOC score of 4.4/10. Trading at $0.99, separating genuine undervalued opportunities from value traps is essential, as detailed by our model data.
The short answer: 1 of 2 CirclFi valuation models project upside for Allarity Therapeutics, Inc. (ALLR) at $0.99 — the models are evenly split, with a Quality Score of 4.4/10 and Value-Trap risk of 51/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Allarity Therapeutics, Inc. (ALLR) in 2026?
What Is the Bull Case vs the Bear Case for Allarity Therapeutics, Inc. (ALLR)?
| Bull case — $1.15 target (+16.3%) | Bear case — $0.97 target (-1.3%) |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, the PWERM model targets a fair value of $1.15 (+16.3%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Quality of Company (QOC) framework, Allarity Therapeutics, Inc.'s rating of 4.4/10 indicates below-average quality, raising questions about sustainable earnings levels. |
| Industry tailwind: platform technology validation could provide meaningful support for Allarity Therapeutics, Inc.'s revenue and margin trajectory in the Biotechnology space. | According to the CirclFi Value Trap algorithm, the stock shows moderate caution signals, meaning investors should verify that apparent undervaluation isn't masking declining business quality. |
| Industry headwind: dilutive capital raises represents a meaningful risk for Allarity Therapeutics, Inc. and its Biotechnology peers. |
How Does ALLR Compare to Its Biotechnology Peers?
Valuation data pages: HOWL · ONCY · ACHV · VERU · IMNN · NWBO · NCEL · CELZ · CABA · EXEL · INCY
Which Other Stocks Score Like ALLR on Quality?
Closest companies to ALLR’s Quality of Company score of 4.4/10, across all industries.
Which Biotechnology Screens Does ALLR Appear In?
So Is Allarity Therapeutics, Inc. (ALLR) Worth Buying in 2026?
Our models don't have a clear verdict on Allarity Therapeutics, Inc.. At $0.99 vs. $1.06 median fair value, the median upside of +7.5% masks significant model disagreement (+17.6% spread). With quality at 4.4/10, this is a stock where the margin of error is wide and additional fundamental research is strongly recommended.
These are quantitative model outputs, not investment recommendations. Allarity Therapeutics, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About ALLR Stock?
Should I buy ALLR stock right now?
Based on CirclFi's multi-model analysis, 1 of 2 models see upside for ALLR at $0.99. The models are divided, which means the investment case depends heavily on your assumptions about Allarity Therapeutics, Inc.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Allarity Therapeutics, Inc.?
Key risks include: an elevated Value Trap score of 51/100, suggesting apparent undervaluation may mask deteriorating fundamentals; a below-average Quality Score of 4.4/10, indicating fundamental weakness; limited model coverage (2/13 active), reducing analytical confidence; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does ALLR compare to its competitors?
Among Biotechnology peers, ALLR holds a Quality Score of 4.4/10. Comparable companies include HOWL (QOC 4.5), ONCY (QOC 4.4), ACHV (QOC 4.5). The relative ranking helps investors identify whether ALLR offers better fundamental quality than alternatives in the same sector.
Is ALLR a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ALLR's Quality Score of 4.4/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.
What price should I buy ALLR at?
CirclFi does not provide target buy prices or price alerts. However, our 2 active models produce fair value estimates ranging from $0.97 to $1.15. At $0.99, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for ALLR.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad